Showing 21,821 - 21,840 results of 22,018 for search '"33 ', query time: 0.11s Refine Results
  1. 21821
  2. 21822
  3. 21823
  4. 21824
  5. 21825

    Comparative analysis of C-Reactive protein levels among Non-comorbid, Comorbid, and Multimorbid Hospitalized COVID-19 patients by Maria Shoukat, Haseeb Khan, Moona Nazish, Abdur Rehman, Sheharyar Raashid, Saad Ahmed, Wajid Munir, Abdulwahed Fahad Alrefaei, Massab Umair, Muhammad Osama Bin Abid, Nasim Akhtar, Wajid Zaman, Malik Badshah

    Published 2025-01-01
    “…The most prevalent comorbidities observed in COVID-19 patients in this study were hypertension (42.1%), diabetes (33.8%), ischemic heart disease (16.5%), asthma (11.2%), chronic kidney disease (7.9%) and Tuberculosis (1.9%). …”
    Get full text
    Article
  6. 21826
  7. 21827

    تدوین راهبردهای سازگاری با خشکسالی در استان لرستان با استفاده از مدل SWOT by کیانفر پیامنی, ابراهیم کریمی سنگچینی, ایرج ویس کرمی, مهران زند

    Published 2023-12-01
    “…فقدان برنامه‌ریزی و سازمان‌دهی مناسب برای پایش و ارزیابی خشکسالی با وزن 0.33، دارای اثربخشی بسیار بالایی در بین عوامل ضعف سازگاری با خشکسالی در استان دارد. …”
    Get full text
    Article
  8. 21828
  9. 21829

    Effects of non-pharmacological interventions on depressive and anxiety symptoms in pregnant women: a systematic review and network meta-analysisResearch in context by Guowei Zeng, Jianfeng Niu, Ke Zhu, Fei Li, Liwen Li, Kaiming Gao, Yanlong Zhuang, Boyang Zhang, Xiaoqiang Han, Gang Ye, Zhikun Gao, Haobai Li

    Published 2025-01-01
    “…Subgroup analysis shows that, in addition to mindfulness therapy, mind-body exercises (SUCRA = 67.43%; SMD = −0.97, 95% CrI = −1.61, −0.33; N = 382) and cognitive-behavioral therapy (SUCRA = 52.60%; SMD = −0.74, 95% CrI = −1.38, −0.09; N = 480) may also be effective in alleviating anxiety symptoms among healthy pregnant women. …”
    Get full text
    Article
  10. 21830
  11. 21831
  12. 21832
  13. 21833
  14. 21834

    The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

    Published 2024-09-01
    “…This study seeks to scrutinize survival discrepancies between various metastatic patterns (M1c1 and M1c2) and pinpoint metabolites associated with treatment outcomes in NSCLC patients undergoing first‐line ICIs combined with chemotherapy. Method In this study, 33 NSCLC patients lacking driver gene mutations diagnosed with M1c1, and 22 similarly diagnosed with M1c2 according to the 9th edition of TNM Classification, were enrolled. …”
    Get full text
    Article
  15. 21835
  16. 21836
  17. 21837
  18. 21838
  19. 21839

    Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer by Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff

    Published 2024-01-01
    “…Patients with right-sided tumors had worse overall survival than left-sided (6.2 months vs 10.1 months; p = 0.003) but presented a better objective response rate with panitumumab (8.3 % [I + P] vs 3.3 % [I + C]). There were more infusion reactions with cetuximab. …”
    Get full text
    Article
  20. 21840